Seeking Alpha

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences (SGHT), Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology ...
Seeking Alpha

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment ...
USA Today

New FDA-cleared Tixel i® revolutionizes dry eye relief

Millions of people suffer from dry eye disease, frequently due to meibomian gland dysfunction (MGD). According to Dr. April Jasper of Advanced Eye Care Specialists, “Dry eye disease occurs when tears ...
Healio

Single TearCare treatment improves visual function, quality of life in dry eye disease

Please provide your email address to receive an email when new articles are posted on . More than half of participants experienced improvement in reading speed after one treatment with TearCare.
Nasdaq

Sight Sciences Announces Cost Savings Findings from TearCare® System Budget Impact Analysis for Dry Eye Disease Treatment

Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...
Women's Health

Why You Have Dry Eyes—And How To Treat Them

Add this to the list of unfair realities: Some women are at higher risk for dry eye than men, thanks to hormonal changes. "Estrogen and androgen levels play a key role in regulating the function of ...